List of Tables
    Table 1. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Opportunities & Trends in Global Market
    Table 2. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Drivers in Global Market
    Table 3. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Restraints in Global Market
    Table 4. Key Players of Cancer Monoclonal Antibody Partnering Terms and Agreements in Global Market
    Table 5. Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players in Global Market, Ranking by Revenue (2021)
    Table 6. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Companies, (US$, Mn), 2017-2022
    Table 7. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Share by Companies, 2017-2022
    Table 8. Global Companies Cancer Monoclonal Antibody Partnering Terms and Agreements Product Type
    Table 9. List of Global Tier 1 Cancer Monoclonal Antibody Partnering Terms and Agreements Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 10. List of Global Tier 2 and Tier 3 Cancer Monoclonal Antibody Partnering Terms and Agreements Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 11. By Type – Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2021 & 2028
    Table 12. By Type - Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global (US$, Mn), 2017-2022
    Table 13. By Type - Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global (US$, Mn), 2023-2028
    Table 14. By Application – Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2021 & 2028
    Table 15. By Application - Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global (US$, Mn), 2017-2022
    Table 16. By Application - Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in Global (US$, Mn), 2023-2028
    Table 17. By Region – Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2021 & 2028
    Table 18. By Region - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), 2017-2022
    Table 19. By Region - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), 2023-2028
    Table 20. By Country - North America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2022
    Table 21. By Country - North America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2023-2028
    Table 22. By Country - Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2022
    Table 23. By Country - Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2023-2028
    Table 24. By Region - Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2022
    Table 25. By Region - Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2023-2028
    Table 26. By Country - South America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2022
    Table 27. By Country - South America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2023-2028
    Table 28. By Country - Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2022
    Table 29. By Country - Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2023-2028
    Table 30. 3SBio Corporate Summary
    Table 31. 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
    Table 32. 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
    Table 33. 4D Pharma Corporate Summary
    Table 34. 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
    Table 35. 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
    Table 36. Abbvie Corporate Summary
    Table 37. Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
    Table 38. Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
    Table 39. Abzena Corporate Summary
    Table 40. Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
    Table 41. Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
    Table 42. Adaptive Biotechnologies Corporate Summary
    Table 43. Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
    Table 44. Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
    Table 45. Aeglea BioTherapeutics Corporate Summary
    Table 46. Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
    Table 47. Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
    Table 48. Agenus Bio Corporate Summary
    Table 49. Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
    Table 50. Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
    Table 51. Ascension Corporate Summary
    Table 52. Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
    Table 53. Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
    Table 54. Ascentage Pharma Corporate Summary
    Table 55. Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
    Table 56. Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
    Table 57. Aslan Pharma Corporate Summary
    Table 58. Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
    Table 59. Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
    Table 60. Telix Pharmaceuticals Corporate Summary
    Table 61. Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
    Table 62. Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
    Table 63. Basilea Pharmaceutica Corporate Summary
    Table 64. Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
    Table 65. Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
    Table 66. Bavarian Nordic Corporate Summary
    Table 67. Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
    Table 68. Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
    Table 69. Baxalta Corporate Summary
    Table 70. Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
    Table 71. Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
    Table 72. Bayer Corporate Summary
    Table 73. Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
    Table 74. Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
    Table 75. Cantargia Corporate Summary
    Table 76. Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
    Table 77. Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
    Table 78. Apollomics Corporate Summary
    Table 79. Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
    Table 80. Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
    Table 81. Chiome Bioscience Corporate Summary
    Table 82. Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
    Table 83. Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
    Table 84. Clovis Oncology Corporate Summary
    Table 85. Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Product Offerings
    Table 86. Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (US$, Mn), (2017-2022)
List of Figures
    Figure 1. Cancer Monoclonal Antibody Partnering Terms and Agreements Segment by Type in 2021
    Figure 2. Cancer Monoclonal Antibody Partnering Terms and Agreements Segment by Application in 2021
    Figure 3. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Overview: 2021
    Figure 4. Key Caveats
    Figure 5. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size: 2021 VS 2028 (US$, Mn)
    Figure 6. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, 2017-2028 (US$, Mn)
    Figure 7. The Top 3 and 5 Players Market Share by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in 2021
    Figure 8. By Type - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share, 2017-2028
    Figure 9. By Application - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share, 2017-2028
    Figure 10. By Region - Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share, 2017-2028
    Figure 11. By Country - North America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share, 2017-2028
    Figure 12. US Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
    Figure 13. Canada Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
    Figure 14. Mexico Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
    Figure 15. By Country - Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share, 2017-2028
    Figure 16. Germany Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
    Figure 17. France Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
    Figure 18. U.K. Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
    Figure 19. Italy Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
    Figure 20. Russia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
    Figure 21. Nordic Countries Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
    Figure 22. Benelux Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
    Figure 23. By Region - Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share, 2017-2028
    Figure 24. China Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
    Figure 25. Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
    Figure 26. South Korea Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
    Figure 27. Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
    Figure 28. India Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
    Figure 29. By Country - South America Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share, 2017-2028
    Figure 30. Brazil Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
    Figure 31. Argentina Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
    Figure 32. By Country - Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share, 2017-2028
    Figure 33. Turkey Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
    Figure 34. Israel Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
    Figure 35. Saudi Arabia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
    Figure 36. UAE Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue, (US$, Mn), 2017-2028
    Figure 37. 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 38. 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 39. Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 40. Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 41. Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 42. Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 43. Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 44. Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 45. Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 46. Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 47. Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 48. Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 49. Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 50. Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 51. Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 52. Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 53. Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 54. Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 55. Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Year Over Year Growth (US$, Mn) & (2017-2022)